Literature DB >> 12833135

Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells.

Norimoto Nakahara1, Ian F Pollack, Walter J Storkus, Toshihiko Wakabayashi, Jun Yoshida, Hideho Okada.   

Abstract

As type I interferons (IFNs) enhance the stimulatory activity of dendritic cells (DCs), we hypothesized that transfection of glioma cells with the IFN-beta gene in the presence of DCs would provide particularly effective antitumor activity by both facilitating apoptosis of glioma cells and presenting the resulting glioma antigens to T cell by DCs, thereby inducing specific T-cell responses against glioma cells. A mouse glioma cell line 203G was first transfected with cDNA encoding IFN-beta using cationic liposomes, then cocultured with syngeneic bone marrow-derived DCs and naïve splenic T cells. The 203G cells were almost completely killed following 96-hour coculture with DCs and T cells, and strong tumor-specific cytotoxic T-lymphocyte (CTL) activity accompanied by high level interleukin (IL)-12 and IFN-gamma production was observed in culture. In addition, omission of either IFN-beta gene delivery, DCs or T cells from the coculture completely abrogated the induction of the CTL activity, suggesting that the combination of these components was required to elicit an optimal effect. On the basis of these in vitro data, syngeneic animals bearing subcutaneous 203G tumors received intratumoral injections of IFN-beta gene and DCs. Suppression of the tumor growth by this combinational therapy was superior to treatment with DC or IFN-beta gene solely. This combination may constitute a new therapeutic strategy to induce potent antiglioma immune responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12833135     DOI: 10.1038/sj.cgt.7700598

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  9 in total

1.  Integration of epidemiology, immunobiology, and translational research for brain tumors.

Authors:  Hideho Okada; Michael E Scheurer; Saumendra N Sarkar; Melissa L Bondy
Journal:  Ann N Y Acad Sci       Date:  2013-05       Impact factor: 5.691

Review 2.  Cytokine networks in glioma.

Authors:  Kenichiro Iwami; Atsushi Natsume; Toshihiko Wakabayashi
Journal:  Neurosurg Rev       Date:  2011-06-09       Impact factor: 3.042

Review 3.  Gene therapy and targeted toxins for glioma.

Authors:  Maria G Castro; Marianela Candolfi; Kurt Kroeger; Gwendalyn D King; James F Curtin; Kader Yagiz; Yohei Mineharu; Hikmat Assi; Mia Wibowo; A K M Ghulam Muhammad; David Foulad; Mariana Puntel; Pedro R Lowenstein
Journal:  Curr Gene Ther       Date:  2011-06       Impact factor: 4.391

Review 4.  Gene therapy and targeted toxins for glioma.

Authors:  Gwendalyn D King; James F Curtin; Marianela Candolfi; Kurt Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

5.  Human umbilical cord matrix-derived stem cells expressing interferon-beta gene significantly attenuate bronchioloalveolar carcinoma xenografts in SCID mice.

Authors:  Takaya Matsuzuka; Raja Shekar Rachakatla; Chiyo Doi; Dharmendra Kumar Maurya; Naomi Ohta; Atsushi Kawabata; Marla M Pyle; Lara Pickel; Jennifer Reischman; Frank Marini; Deryl Troyer; Masaaki Tamura
Journal:  Lung Cancer       Date:  2010-10       Impact factor: 5.705

6.  Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors.

Authors:  Manabu Hatano; Naruo Kuwashima; Tomohide Tatsumi; Jill E Dusak; Fumihiko Nishimura; Karlyne M Reilly; Walter J Storkus; Hideho Okada
Journal:  J Transl Med       Date:  2004-11-24       Impact factor: 5.531

7.  Dendritic cell-glioma fusion activates T lymphocytes by elevating cytotoxic efficiency as an antitumor vaccine.

Authors:  Fuming Tian; Changwu Dou; Songtao Qi; Bo Chen; Liqun Zhao; Xiaojuan Wang
Journal:  Cent Eur J Immunol       Date:  2014-10-14       Impact factor: 2.085

8.  Interferon-β gene-modified human bone marrow mesenchymal stem cells attenuate hepatocellular carcinoma through inhibiting AKT/FOXO3a pathway.

Authors:  C Xie; D-Y Xie; B-L Lin; G-L Zhang; P-P Wang; L Peng; Z-L Gao
Journal:  Br J Cancer       Date:  2013-07-25       Impact factor: 7.640

9.  Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells.

Authors:  Fabian Wolpert; Caroline Happold; Guido Reifenberger; Ana-Maria Florea; René Deenen; Patrick Roth; Marian Christoph Neidert; Katrin Lamszus; Manfred Westphal; Michael Weller; Günter Eisele
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.